Navigation Links
Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
Date:4/25/2008

HAYWARD, Calif., April 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) will announce its first quarter 2008 financial results on Thursday, May 1, 2008, after market close.

The announcement of Kosan's first quarter 2008 financial results will be followed by a conference call and live webcast on May 1, 2008 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 888.680.0878 (US) or 617.213.4855 (international), access code 63268386. To pre-register for the call, go to https://www.theconferencingservice.com/prereg/key.process?key=PLGLKCFUP or visit the "Investors/Press" page at http://www.kosan.com.

Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the "Webcasts" tab under the heading, "Investors/Press."

The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through May 8, 2008 by dialing 888-286-8010, access code: 17626068. International callers can dial 617-801-6888, access code: 17626068.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
2. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
3. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
4. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
5. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
6. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
7. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
8. Kosan Announces February 28, 2008 Conference Call and Webcast
9. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
10. Kosan Announces Third Quarter 2007 Financial Results
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... ... September 13, 2017 , ... AMRI, ... industry to improve patient outcomes and quality of life for more than 25 ... named a US expert to the International Standards Organization/Technical Committee 194: Biological ...
(Date:9/12/2017)... NJ (PRWEB) , ... September 12, 2017 , ... ... of the fastest growing b2b product testing and development companies will be exhibiting ... service offerings. , Contract Pharma is an educational conference ...
(Date:9/12/2017)... ... 12, 2017 , ... Soybean researchers seeking funding from the ... by October 15, prior to completing a full grant application. , “The pre-proposal ... priorities, and to encourage researchers to further develop ones that might need more ...
(Date:9/12/2017)... ... 2017 , ... Facet Life Sciences, a leading provider of development solutions (software ... PhD has joined the company’s Board of Directors. , Dr. Massa brings 38 ... Most recently he served as VP and Head of Global Regulatory Operations at Sanofi. ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):